Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Burkholderia pseudomallei Infections (Melioidosis) - Overview
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development
Aceragen Inc
AN2 Therapeutics Inc
Bugworks Research Inc
Entasis Therapeutics Holdings Inc
Soligenix Inc
Burkholderia pseudomallei Infections (Melioidosis) - Drug Profiles
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
History of Events
BWC-0977 - Drug Profile
Product Description
Mechanism Of Action
History of Events
epetraborole - Drug Profile
Product Description
Mechanism Of Action
History of Events
fusidic acid - Drug Profile
Product Description
Mechanism Of Action
History of Events
melioidosis vaccine - Drug Profile
Product Description
Mechanism Of Action
POLB-003 - Drug Profile
Product Description
Mechanism Of Action
SGX-943 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products
Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones
Featured News & Press Releases
Jun 15, 2022: Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis
May 18, 2022: Poolbeg Pharma : European Melioidosis Congress
Jan 05, 2022: Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for development of ACG-701 as medical countermeasure against melioidosis
Apr 26, 2021: Bugworks secures funding from US Government’s Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
Nov 27, 2017: Soligenix Announces Presentation of Data on Dusquetide at Chemical and Biological Defense Science and Technology Conference
May 31, 2016: FDA Grants Soligenix “Fast Track” Desigtion for SGX943 for the Treatment of Melioidosis
Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Aceragen Inc, 2022
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by AN2 Therapeutics Inc, 2022
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bugworks Research Inc, 2022
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix Inc, 2022
Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, 2022
Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, 2022